CX5 Stock Overview
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
LadRx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.056 |
| 52 Week High | US$21.80 |
| 52 Week Low | US$0.056 |
| Beta | 1.71 |
| 1 Month Change | 0% |
| 3 Month Change | -99.00% |
| 1 Year Change | -99.44% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| CX5 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | -1.0% |
| 1Y | -99.4% | -22.4% | 2.0% |
Return vs Industry: CX5 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: CX5 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| CX5 volatility | |
|---|---|
| CX5 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CX5's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CX5's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 3 | Stephen Snowdy | www.ladrxcorp.com |
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company’s Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer.
LadRx Corporation Fundamentals Summary
| CX5 fundamental statistics | |
|---|---|
| Market cap | €905.08k |
| Earnings (TTM) | -€4.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs CX5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CX5 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.40m |
| Earnings | -US$4.40m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.89 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CX5 perform over the long term?
See historical performance and comparison